Incidence and Residual Risk of HIV, HBV and HCV Infections Among Blood Donors in Tehran

• Published in: Indian journal of hematology & blood transfusion Vol. 33; no. 3; pp. 412 - 416
• Main Authors: Saber, Hamid Reza, Tabatabaee, Seyed Morteza, Abasian, Ali, Jamali, Mostafa, SalekMoghadam, Ebadollah, Hajibeigi, Bashir, Alavian, Seyed Moayed, Mirrezaie, Seyed Mohammad
• Format: Journal Article
• Language: English
• Published: New Delhi Springer India 01.09.2017; Springer Nature B.V
• Subjects: Blood & organ donations; Blood Transfusion Medicine; Hematology; Hepatitis; HIV; Human Genetics; Human immunodeficiency virus; Medicine; Medicine & Public Health; Oncology; Original; Original Article; Patient safety; Risk management; Viral infections; Incidence estimation; Iran; Residual risk; Blood donors
• ISSN: 0971-4502; 0974-0449; 0974-0449; 0971-4502
• DOI: 10.1007/s12288-016-0732-5

Estimation of residual risk is essential to monitor and improve blood safety. Our epidemiologic knowledge in the Iranian donor population regarding transfusion transmitted viral infections (TTIs), is confined to a few studies based on prevalence rate. There are no reports on residual risk of TTIs in Iran. In present survey, a software database of donor records of Tehran Blood Transfusion Center (TBTC) was used to estimate the incidence and residual risk of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections, by applying the incidence rate/window period (IR-WP) model. A total of 1,207,155 repeat donations was included in the analysis and represented a mean of 8.4 donations per donor over 6 years. The incidence amongst repeat donors was estimated by dividing the number of confirmed seroconverting donors by the total number of person-years at risk. The residual risk was calculated using the incidence/window period model. Incidence rate and residual risk for HBV, HCV and HIV infections were calculated for total (2005–2010) and two consecutive periods (2005–2007 and 2008–2010) of the study. According to the IR-WP model, overall residual risk for HIV and HCV in the total study period was 0.4 and 12.5 per million units, respectively and for HBV 4.57/100,000 donations. The incidence and residual risk of TTIs, calculated on TBTC’s blood supply was low and comparable with developed countries for HIV infection but high for HCV and HBV infections. Blood safety may therefore be better managed by applying other techniques like nucleic acid amplification tests.